Fast-ageing placentas may drive late-onset pre-eclampsia, Flinders study finds

Placentas from pregnancies affected by late-onset pre-eclampsia show clear signs of ageing faster than they should, a study led by Flinders University in Australia has found. The work, led by Dr Anya Arthurs and published in the Proceedings of the National Academy of Sciences (PNAS), was announced by the university on Monday, October 26, 2026. The team found shorter telomeres, more DNA damage and a build-up of worn-out cells in affected placentas, and pointed to oxidative stress as a major driver.

Pre-eclampsia is a pregnancy disorder marked by high blood pressure. The World Health Organization describes it as a hypertensive disorder that usually develops after the 20th week of pregnancy. It can harm both the mother and the baby, and doctors still have few tools to prevent it. The late-onset form appears later in pregnancy and is the more common type, but it has been harder to explain than the early-onset form.

The placenta is the organ that grows in the womb to feed the baby and remove waste. It is built to last only about nine months, so it ages much faster than the rest of the body. The new study suggests that in late-onset pre-eclampsia this normal ageing runs ahead of schedule. Telomeres, the protective caps at the ends of chromosomes, become shorter as cells age; in the affected placentas they were shorter than in healthy ones. The team also found more cells that had entered senescence, a state in which cells stop dividing and can release signals that inflame nearby tissue.

According to the university, Dr Arthurs argued that placental ageing may be an active process that helps cause pre-eclampsia, rather than only a side effect of the disease. If that view holds up, it changes where researchers look for prevention. Oxidative stress, a chemical imbalance that damages cells, appeared to be a key driver, and easing it in the lab models reduced several ageing markers. The role of TERRA adds a second lead: when its level fell, the lab-grown tissue aged faster.

For women, the practical message today is about awareness rather than treatment. The study does not offer a test or a drug. It gives scientists a clearer target, and it underlines why regular blood pressure checks in the second half of pregnancy matter. Any decision about care belongs with a woman's own doctor.

Short-term: The study gives researchers a defined set of ageing markers to measure in placentas, and a lab model in which to test ways of lowering oxidative stress. It does not change medical advice for pregnant women now.

Long-term: If later studies confirm that faster placental ageing helps cause late-onset pre-eclampsia, it could lead to early warning tests based on these markers and, in time, to treatments that slow the ageing process. The researchers say much more work is needed before any such therapy could be used in pregnancy.

Who is affected: Pregnant women, especially those in the later months of pregnancy; obstetricians and midwives; and researchers in maternal health. In countries with large numbers of births, such as India, even a small share of affected pregnancies means many women.

Questions and Answers